ResearcherSun Yat-sen UniversityActive in the last 2 years
Wei Zhao
Matched on ORCID iD 0000-0002-0774-2571; OpenAlex author ID A5030517242. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 13
2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper
Papers 6
- CSNK2A1 confers gemcitabine resistance to pancreatic ductal adenocarcinoma via inducing autophagy. Co-author DOI 10.1016/j.canlet.2024.216640↗
- SUMO specific peptidase 3 halts pancreatic ductal adenocarcinoma metastasis via deSUMOylating DKC1. Co-author DOI 10.1038/s41418-023-01175-4↗
- ACLP promotes activation of cancer-associated fibroblasts and tumor metastasis via ACLP-PPARγ-ACLP feedback loop in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.215802↗
- HNRNPC impedes m6A-dependent anti-metastatic alternative splicing events in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2021.07.016↗
- Targeting Super-Enhancers via Nanoparticle-Facilitated BRD4 and CDK7 Inhibitors Synergistically Suppresses Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1002/advs.201902926↗
- The C/EBPβ-LINC01133 axis promotes cell proliferation in pancreatic ductal adenocarcinoma through upregulation of CCNG1. Co-author DOI 10.1016/j.canlet.2018.02.020↗
Closest collaborators
The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Xiao-Yu Yin · 5 shared papers, 2018–2024 · strength 0.75
- Paper CSNK2A1 confers gemcitabine resistance to pancreatic ductal adenocarcinoma via inducing autophagy. DOI 10.1016/j.canlet.2024.216640↗
- Paper SUMO specific peptidase 3 halts pancreatic ductal adenocarcinoma metastasis via deSUMOylating DKC1. DOI 10.1038/s41418-023-01175-4↗
- Paper ACLP promotes activation of cancer-associated fibroblasts and tumor metastasis via ACLP-PPARγ-ACLP feedback loop in pan… DOI 10.1016/j.canlet.2022.215802↗
- Xiao‐Xu Zhu · 4 shared papers, 2018–2023 · strength 0.57
- Paper SUMO specific peptidase 3 halts pancreatic ductal adenocarcinoma metastasis via deSUMOylating DKC1. DOI 10.1038/s41418-023-01175-4↗
- Paper ACLP promotes activation of cancer-associated fibroblasts and tumor metastasis via ACLP-PPARγ-ACLP feedback loop in pan… DOI 10.1016/j.canlet.2022.215802↗
- Paper HNRNPC impedes m6A-dependent anti-metastatic alternative splicing events in pancreatic ductal adenocarcinoma. DOI 10.1016/j.canlet.2021.07.016↗
- Xi‐Tai Huang · 4 shared papers, 2018–2024 · strength 0.51
- Paper CSNK2A1 confers gemcitabine resistance to pancreatic ductal adenocarcinoma via inducing autophagy. DOI 10.1016/j.canlet.2024.216640↗
- Paper HNRNPC impedes m6A-dependent anti-metastatic alternative splicing events in pancreatic ductal adenocarcinoma. DOI 10.1016/j.canlet.2021.07.016↗
- Paper Targeting Super-Enhancers via Nanoparticle-Facilitated BRD4 and CDK7 Inhibitors Synergistically Suppresses Pancreatic D… DOI 10.1002/advs.201902926↗
- Ya-Xiong Li · 2 shared papers, 2022–2023 · strength 0.34
- Xiao Feng Wu · 2 shared papers, 2022–2023 · strength 0.34
- Xuhao Ni · 2 shared papers, 2022–2023 · strength 0.34
- Chen‐Song Huang · 3 shared papers, 2018–2021 · strength 0.33
- Paper HNRNPC impedes m6A-dependent anti-metastatic alternative splicing events in pancreatic ductal adenocarcinoma. DOI 10.1016/j.canlet.2021.07.016↗
- Paper Targeting Super-Enhancers via Nanoparticle-Facilitated BRD4 and CDK7 Inhibitors Synergistically Suppresses Pancreatic D… DOI 10.1002/advs.201902926↗
- Paper The C/EBPβ-LINC01133 axis promotes cell proliferation in pancreatic ductal adenocarcinoma through upregulation of CCNG1. DOI 10.1016/j.canlet.2018.02.020↗
- Jie‐Qin Wang · 2 shared papers, 2020–2024 · strength 0.28
- Yin-Hao Shi · 1 shared paper, 2024 · strength 0.18
- Ying‐Qin Zhu · 1 shared paper, 2024 · strength 0.18
- Mingjian Ma · 1 shared paper, 2024 · strength 0.18
- Zhide Liu · 1 shared paper, 2024 · strength 0.18
- Xiaoyu Yin · 1 shared paper, 2020 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.